SCHEMBL6323740

SCHEMBL6323740

Nc1onc(-c2ccc(-c3cccc(Cl)c3)o2)c1C(=O)NC(Cc1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
TP53 P04637 3/20 0.41
DCAF1 Q9Y4B6 2/20 0.41
TACR3 P29371 1/20 0.41
C3AR1 Q16581 1/20 0.40
ERAP2 Q6P179 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38
LNPEP Q9UIQ6 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
NCOA1 Q15788 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
CNR2 P34972 1/20 0.38
MMEL1 Q495T6 1/20 0.38
POLB P06746 1/20 0.38
S1PR1 P21453 1/20 0.37
S1PR3 Q99500 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314911 0.87 CYP1A2 (0.45) MAPTTACR3ALDH1A1SMN1; SMN2POLB
SCHEMBL6321664 0.87 S1PR1 (0.47) MAPTTP53C3AR1ALDH1A1POLB
SCHEMBL6316282 0.86 CA1 (0.50) TACR3ALDH1A1HTTNCOA1SMN1; SMN2
SCHEMBL6317081 0.85 THRB (0.49) ALDH1A1
SCHEMBL6323341 0.83 MAPT (0.46) MAPTTP53C3AR1ERAP2ERAP1
SCHEMBL6324193 0.83 MAPT (0.47) MAPTTP53C3AR1ALDH1A1HTT
SCHEMBL6317577 0.82 ALDH1A1 (0.43) TACR3ALDH1A1HTTNCOA1SMN1; SMN2
SCHEMBL6318123 0.82 MLLT1 (0.44) MAPTTP53ALDH1A1SMN1; SMN2POLB
SCHEMBL6319732 0.82 MAPT (0.63) MAPTTP53ALDH1A1HTT
SCHEMBL6316350 0.82 TP53 (0.41) MAPTTP53C3AR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPT 281/4885TP53 609/4885DCAF1 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.